
2020 ADA Guidelines Include SGLT2 Inhibitors, GLP-1 Receptor Agonists to Treat Comorbidities
Although there were many updates in various facets of diabetes care, one change stood out. New recommendations call for 2 drug classes to be used to treat patients with type 2 diabetes (T2D) and comorbidities: sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists.
In its annual revision of the
Although there were many updates in various facets of diabetes care, one change stood out. New recommendations call for 2 drug classes to be used to treat patients with type 2 diabetes (T2D) and comorbidities: sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. According to
In the section entitled Pharmacologic Approaches to Glycemic Treatment, authors state the inhibitors “should be considered for patients when atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease predominates independent of [glycated hemoglobin] A1C.”
SGLT2 inhibitors induce a
This inclusion is a welcome step, as it provides concrete rules for prescribing the treatments.
Speaking with The American Journal of Managed Care® regarding the 2018 American College of Cardiology (ACC) Expert Consensus Decision Pathway, Javed Butler, MD, a professor and chairman of the Department of Medicine at the University of Mississippi,
The
Separate additions to the guidelines include updates to technological advances in treatment, expanded research on psychological impacts of the disease, and new recommendations regarding care of pregnant women with diabetes.
“The field of diabetes care is rapidly changing as new research, technology, and treatments that can improve the health and well-being of people with diabetes continue to emerge,” said the authors.
The ADA has updated the Standards of Medical Care in Diabetes every year since 1989, although the group now issues midyear updates for major clinical advances.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.